Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Circulating tumor DNA as a novel tool to shape clinical trial designs with the potential to impact outcomes: a focus on PI3K inhibitors.

Sellami D, Dharan B, Wilke C, Scherer SJ, Hirawat S.

Ann Oncol. 2017 Nov 1;28(11):2882-2887. doi: 10.1093/annonc/mdx480. Review. No abstract available.

PMID:
28950291
2.

Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib.

Germa C, Miller M, Mukhopadhyay P, Hewes B, Caponigro G, Scherer SJ, Hirawat S.

Ann Oncol. 2017 Aug 1;28(8):2021-2024. doi: 10.1093/annonc/mdx226. No abstract available.

3.

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB.

Adv Anat Pathol. 2017 Nov;24(6):311-335. doi: 10.1097/PAP.0000000000000161. Review.

PMID:
28777143
4.

Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB.

Adv Anat Pathol. 2017 Sep;24(5):235-251. doi: 10.1097/PAP.0000000000000162. Review.

PMID:
28777142
5.

HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib.

Press MF, Ellis CE, Gagnon RC, Grob TJ, Buyse M, Villalobos I, Liang Z, Wu S, Bang YJ, Qin SK, Chung HC, Xu J, Park JO, Jeziorski K, Afenjar K, Ma Y, Estrada MC, Robinson DM, Scherer SJ, Sauter G, Hecht JR, Slamon DJ.

Mol Cancer Ther. 2017 Jan;16(1):228-238. doi: 10.1158/1535-7163.MCT-15-0887. Epub 2016 Nov 3.

6.

Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection.

Stremitzer S, Zhang W, Yang D, Ning Y, Sunakawa Y, Matsusaka S, Parekh A, Okazaki S, Hanna D, Astrow SH, Moran M, Hernandez J, Stephens C, Scherer SJ, Stift J, Wrba F, Gruenberger T, Lenz HJ.

Mol Cancer Ther. 2016 Nov;15(11):2814-2821. Epub 2016 Aug 17.

7.

Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab.

Zhou C, Clamp A, Backen A, Berzuini C, Renehan A, Banks RE, Kaplan R, Scherer SJ, Kristensen GB, Pujade-Lauraine E, Dive C, Jayson GC.

Br J Cancer. 2016 Jul 12;115(2):228-35. doi: 10.1038/bjc.2016.194. Epub 2016 Jun 28.

8.

Evaluation of Angiopoietin-2 as a biomarker in gastric cancer: results from the randomised phase III AVAGAST trial.

Hacker UT, Escalona-Espinosa L, Consalvo N, Goede V, Schiffmann L, Scherer SJ, Hedge P, Van Cutsem E, Coutelle O, Büning H.

Br J Cancer. 2016 Apr 12;114(8):855-62. doi: 10.1038/bjc.2016.30. Epub 2016 Mar 31.

9.

Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials.

Sunakawa Y, Stintzing S, Cao S, Heinemann V, Cremolini C, Falcone A, Yang D, Zhang W, Ning Y, Stremitzer S, Matsusaka S, Yamauchi S, Parekh A, Okazaki S, Berger MD, Graver S, Mendez A, Scherer SJ, Loupakis F, Lenz HJ.

Ann Oncol. 2015 Dec;26(12):2450-6. doi: 10.1093/annonc/mdv474. Epub 2015 Sep 28.

10.

Primary tumor location as a prognostic factor in metastatic colorectal cancer.

Loupakis F, Yang D, Yau L, Feng S, Cremolini C, Zhang W, Maus MK, Antoniotti C, Langer C, Scherer SJ, Müller T, Hurwitz HI, Saltz L, Falcone A, Lenz HJ.

J Natl Cancer Inst. 2015 Feb 24;107(3). pii: dju427. doi: 10.1093/jnci/dju427. Print 2015 Mar.

11.

Predictive tissue biomarkers for bevacizumab-containing therapy in metastatic colorectal cancer: an update.

Marien KM, Croons V, Martinet W, De Loof H, Ung C, Waelput W, Scherer SJ, Kockx MM, De Meyer GR.

Expert Rev Mol Diagn. 2015 Mar;15(3):399-414. doi: 10.1586/14737159.2015.993972. Epub 2015 Jan 13. Review.

PMID:
25585649
12.

89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment.

Oosting SF, Brouwers AH, van Es SC, Nagengast WB, Oude Munnink TH, Lub-de Hooge MN, Hollema H, de Jong JR, de Jong IJ, de Haas S, Scherer SJ, Sluiter WJ, Dierckx RA, Bongaerts AH, Gietema JA, de Vries EG.

J Nucl Med. 2015 Jan;56(1):63-9. doi: 10.2967/jnumed.114.144840. Epub 2014 Dec 4.

13.

Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer.

Volz NB, Stintzing S, Zhang W, Yang D, Ning Y, Wakatsuki T, El-Khoueiry RE, Li JE, Kardosh A, Loupakis F, Cremolini C, Falcone A, Scherer SJ, Lenz HJ.

Pharmacogenomics J. 2015 Feb;15(1):69-76. doi: 10.1038/tpj.2014.40. Epub 2014 Jul 29.

PMID:
25069475
14.

Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy.

de Haas S, Delmar P, Bansal AT, Moisse M, Miles DW, Leighl N, Escudier B, Van Cutsem E, Carmeliet P, Scherer SJ, Pallaud C, Lambrechts D.

Angiogenesis. 2014 Oct;17(4):909-20. doi: 10.1007/s10456-014-9438-1. Epub 2014 Jul 11.

PMID:
25012543
15.

The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer.

Backen A, Renehan AG, Clamp AR, Berzuini C, Zhou C, Oza A, Bannoo S, Scherer SJ, Banks RE, Dive C, Jayson GC.

Clin Cancer Res. 2014 Sep 1;20(17):4549-4558. doi: 10.1158/1078-0432.CCR-13-3248. Epub 2014 Jun 19.

16.

Anti-VEGF-A affects the angiogenic properties of tumor-derived microparticles.

Munster M, Fremder E, Miller V, Ben-Tsedek N, Davidi S, Scherer SJ, Shaked Y.

PLoS One. 2014 Apr 21;9(4):e95983. doi: 10.1371/journal.pone.0095983. eCollection 2014.

17.

Genetic markers of bevacizumab-induced hypertension.

Lambrechts D, Moisse M, Delmar P, Miles DW, Leighl N, Escudier B, Van Cutsem E, Bansal AT, Carmeliet P, Scherer SJ, de Haas S, Pallaud C.

Angiogenesis. 2014 Jul;17(3):685-94. doi: 10.1007/s10456-014-9424-7. Epub 2014 Feb 21.

PMID:
24558090
18.

Tumor-derived microparticles induce bone marrow-derived cell mobilization and tumor homing: a process regulated by osteopontin.

Fremder E, Munster M, Aharon A, Miller V, Gingis-Velitski S, Voloshin T, Alishekevitz D, Bril R, Scherer SJ, Loven D, Brenner B, Shaked Y.

Int J Cancer. 2014 Jul 15;135(2):270-81. doi: 10.1002/ijc.28678. Epub 2014 Jan 13.

19.

Differential therapeutic effects of anti-VEGF-A antibody in different tumor models: implications for choosing appropriate tumor models for drug testing.

Alishekevitz D, Bril R, Loven D, Miller V, Voloshin T, Gingis-Velistki S, Fremder E, Scherer SJ, Shaked Y.

Mol Cancer Ther. 2014 Jan;13(1):202-13. doi: 10.1158/1535-7163.MCT-13-0356. Epub 2013 Oct 22.

20.

Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies.

Brauer MJ, Zhuang G, Schmidt M, Yao J, Wu X, Kaminker JS, Jurinka SS, Kolumam G, Chung AS, Jubb A, Modrusan Z, Ozawa T, James CD, Phillips H, Haley B, Tam RN, Clermont AC, Cheng JH, Yang SX, Swain SM, Chen D, Scherer SJ, Koeppen H, Yeh RF, Yue P, Stephan JP, Hegde P, Ferrara N, Singh M, Bais C.

Clin Cancer Res. 2013 Jul 1;19(13):3681-92. doi: 10.1158/1078-0432.CCR-12-3635. Epub 2013 May 17.

21.

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.

Miles DW, de Haas SL, Dirix LY, Romieu G, Chan A, Pivot X, Tomczak P, Provencher L, Cortés J, Delmar PR, Scherer SJ.

Br J Cancer. 2013 Mar 19;108(5):1052-60. doi: 10.1038/bjc.2013.69. Epub 2013 Feb 19.

22.

Markers of response for the antiangiogenic agent bevacizumab.

Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ.

J Clin Oncol. 2013 Mar 20;31(9):1219-30. doi: 10.1200/JCO.2012.46.2762. Epub 2013 Feb 11. Review.

PMID:
23401453
23.

Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab.

Hegde PS, Jubb AM, Chen D, Li NF, Meng YG, Bernaards C, Elliott R, Scherer SJ, Chen DS.

Clin Cancer Res. 2013 Feb 15;19(4):929-37. doi: 10.1158/1078-0432.CCR-12-2535. Epub 2012 Nov 20.

24.

Tumor-initiating cells of various tumor types exhibit differential angiogenic properties and react differently to antiangiogenic drugs.

Benayoun L, Gingis-Velitski S, Voloshin T, Segal E, Segev R, Munster M, Bril R, Satchi-Fainaro R, Scherer SJ, Shaked Y.

Stem Cells. 2012 Sep;30(9):1831-41. doi: 10.1002/stem.1170.

25.

VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials.

Lambrechts D, Claes B, Delmar P, Reumers J, Mazzone M, Yesilyurt BT, Devlieger R, Verslype C, Tejpar S, Wildiers H, de Haas S, Carmeliet P, Scherer SJ, Van Cutsem E.

Lancet Oncol. 2012 Jul;13(7):724-33. doi: 10.1016/S1470-2045(12)70231-0. Epub 2012 May 17.

PMID:
22608783
26.

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.

Van Cutsem E, de Haas S, Kang YK, Ohtsu A, Tebbutt NC, Ming Xu J, Peng Yong W, Langer B, Delmar P, Scherer SJ, Shah MA.

J Clin Oncol. 2012 Jun 10;30(17):2119-27. doi: 10.1200/JCO.2011.39.9824. Epub 2012 May 7.

PMID:
22565005
27.

Cancer therapy modulates VEGF signaling and viability in adult rat cardiac microvascular endothelial cells and cardiomyocytes.

Chiusa M, Hool SL, Truetsch P, Djafarzadeh S, Jakob SM, Seifriz F, Scherer SJ, Suter TM, Zuppinger C, Zbinden S.

J Mol Cell Cardiol. 2012 May;52(5):1164-75. doi: 10.1016/j.yjmcc.2012.01.022. Epub 2012 Feb 3.

PMID:
22326847
28.

Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment.

Vermaat JS, Nijman IJ, Koudijs MJ, Gerritse FL, Scherer SJ, Mokry M, Roessingh WM, Lansu N, de Bruijn E, van Hillegersberg R, van Diest PJ, Cuppen E, Voest EE.

Clin Cancer Res. 2012 Feb 1;18(3):688-99. doi: 10.1158/1078-0432.CCR-11-1965. Epub 2011 Dec 15.

29.

Interaction of Muc2 and Apc on Wnt signaling and in intestinal tumorigenesis: potential role of chronic inflammation.

Yang K, Popova NV, Yang WC, Lozonschi I, Tadesse S, Kent S, Bancroft L, Matise I, Cormier RT, Scherer SJ, Edelmann W, Lipkin M, Augenlicht L, Velcich A.

Cancer Res. 2008 Sep 15;68(18):7313-22. doi: 10.1158/0008-5472.CAN-08-0598.

30.

Absence of telomerase activity in malignant bone tumors and soft-tissue sarcomas.

Lauer NK, Maier SM, Oberringer M, Schulte M, Mutschler W, Hanselmann RG, Schartl M, Scherer SJ, Wirbel RJ.

Sarcoma. 2002;6(1):43-6. doi: 10.1080/13577140220127549.

31.

Distinct effects of the recurrent Mlh1G67R mutation on MMR functions, cancer, and meiosis.

Avdievich E, Reiss C, Scherer SJ, Zhang Y, Maier SM, Jin B, Hou H Jr, Rosenwald A, Riedmiller H, Kucherlapati R, Cohen PE, Edelmann W, Kneitz B.

Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4247-52. doi: 10.1073/pnas.0800276105. Epub 2008 Mar 12.

32.

The DNA-mismatch repair enzyme hMSH2 modulates UV-B-induced cell cycle arrest and apoptosis in melanoma cells.

Seifert M, Scherer SJ, Edelmann W, Böhm M, Meineke V, Löbrich M, Tilgen W, Reichrath J.

J Invest Dermatol. 2008 Jan;128(1):203-13. Epub 2007 Jul 5.

33.

1[alpha],25-dihydroxyvitamin D(3) enhances annexin II dependent proliferation of osteoblasts.

Maier SM, Scherer SJ, Seifert M, Hanselmann RG, Schleehuber Y, Edelmann L, Reichrath J, Krohne G, Rescher U, Seidl W, Mutschler W, Claes L, Welter C, Schartl M.

J Cell Biochem. 2007 Feb 15;100(3):679-92.

PMID:
16986113
34.

Functional consequences of DNA mismatch repair missense mutations in murine models and their impact on cancer predisposition.

Scherer SJ, Avdievich E, Edelmann W.

Biochem Soc Trans. 2005 Aug;33(Pt 4):689-93. Review.

PMID:
16042575
35.

Dominant effects of an Msh6 missense mutation on DNA repair and cancer susceptibility.

Yang G, Scherer SJ, Shell SS, Yang K, Kim M, Lipkin M, Kucherlapati R, Kolodner RD, Edelmann W.

Cancer Cell. 2004 Aug;6(2):139-50.

36.

Examination of Msh6- and Msh3-deficient mice in class switching reveals overlapping and distinct roles of MutS homologues in antibody diversification.

Li Z, Scherer SJ, Ronai D, Iglesias-Ussel MD, Peled JU, Bardwell PD, Zhuang M, Lee K, Martin A, Edelmann W, Scharff MD.

J Exp Med. 2004 Jul 5;200(1):47-59.

37.

An Msh2 point mutation uncouples DNA mismatch repair and apoptosis.

Lin DP, Wang Y, Scherer SJ, Clark AB, Yang K, Avdievich E, Jin B, Werling U, Parris T, Kurihara N, Umar A, Kucherlapati R, Lipkin M, Kunkel TA, Edelmann W.

Cancer Res. 2004 Jan 15;64(2):517-22.

38.

A putative Sec23 homologue of Plasmodium falciparum is located in Maurer's clefts.

Wickert H, Rohrbach P, Scherer SJ, Krohne G, Lanzer M.

Mol Biochem Parasitol. 2003 Jul;129(2):209-13. No abstract available.

PMID:
12850265
39.

Lack of ultraviolet-light inducibility of the medakafish (Oryzias latipes) tumor suppressor gene p53.

Chen S, Hong Y, Scherer SJ, Schartl M.

Gene. 2001 Feb 21;264(2):197-203.

PMID:
11250074
40.

p53 and c-Jun functionally synergize in the regulation of the DNA repair gene hMSH2 in response to UV.

Scherer SJ, Maier SM, Seifert M, Hanselmann RG, Zang KD, Muller-Hermelink HK, Angel P, Welter C, Schartl M.

J Biol Chem. 2000 Dec 1;275(48):37469-73.

41.

Specific in vitro binding of p53 to the promoter region of the human mismatch repair gene hMSH2.

Scherer SJ, Welter C, Zang KD, Dooley S.

Biochem Biophys Res Commun. 1996 Apr 25;221(3):722-8.

PMID:
8630028
42.

Isolation and characterization of the human mismatch repair gene hMSH2 promoter region.

Scherer SJ, Seib T, Seitz G, Dooley S, Welter C.

Hum Genet. 1996 Jan;97(1):114-6.

PMID:
8557250
44.

Residues of phenthoate (Cidial) and its oxon on grapefruit, lemons, oranges, their fractionated products, and soil.

Moye HA, Brooks RF, Scherer SJ.

J Agric Food Chem. 1983 Jan-Feb;31(1):122-7. No abstract available.

PMID:
6826909

Supplemental Content

Loading ...
Support Center